THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY
Top Cited Papers
- 1 June 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 173 (6), 1938-1942
- https://doi.org/10.1097/01.ju.0000158155.33890.e7
Abstract
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. Materials and Methods: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. Results: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%–92%) to 8% for a score of 7 to 10 (95% CI 0%–28%). The concordance index for the UCSF-CAPRA score was 0.66. Conclusions: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.Keywords
This publication has 22 references indexed in Scilit:
- ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSUREJournal of Urology, 2005
- THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRYJournal of Urology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Assessment of the Enhancement in Predictive Accuracy Provided by Systematic Biopsy in Predicting Outcome for Clinically Localized Prostate CancerJournal of Urology, 2004
- A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate CancerThe New England Journal of Medicine, 2002
- PERCENT PROSTATE NEEDLE BIOPSY TISSUE WITH CANCER IS MORE PREDICTIVE OF BIOCHEMICAL FAILURE OR ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY THAN PROSTATE SPECIFIC ANTIGEN OR GLEASON SCOREJournal of Urology, 2002
- PERCENT PROSTATE NEEDLE BIOPSY TISSUE WITH CANCER IS MORE PREDICTIVE OF BIOCHEMICAL FAILURE OR ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY THAN PROSTATE SPECIFIC ANTIGEN OR GLEASON SCOREJournal of Urology, 2002
- A CATALOG OF PROSTATE CANCER NOMOGRAMSJournal of Urology, 2001
- A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- The capsure database: a methodology for clinical practice and research in prostate cancerUrology, 1996